Displaying 1 - 3 of 3
| Active Ingredient | Metformin/Empagliflozin |
| Therapeutic Class | Sodium Glucose Co-Transporter Inhibitor |
| Indications |
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin. Empagliflozin, when used in combination with metformin, is also ind More ... |
| Caution | Urinary tract infection ,Decreased vitamin B12 levels; Female genital mycotic infections ;Increased urination ;Male genital mycotic infections; Necrotizing fasciitis of the perineum (Fournier’s gangre More ... |
| Dose Range |
Empagliflozin total daily dose: 10 mg For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |
| Active Ingredient | EMPAGLIFLOZIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | Monotherapy or with other antidiabetic medications, including insulin, in the management of type 2 diabetes mellitus; To reduce the risk of cardiovascular death in those with type 2 diabetes mellitus More ... |
| Caution | Urinary tract infection, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, female genital mycotic infections, male genital mycotic infections, and nausea |
| Dose Range | The usual oral dose of empagliflozin is 10 mg once daily, which may be increased to 25 mg daily, if necessary. When given with metformin, empagliflozin may be given in 2 divided doses. Doses of insulin, sulfonylurea, or other insulin secretagogues may nee |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EMPAGLIFLOZIN|METFORMIN |
| Therapeutic Class | SODIUM GLUCOSE CO TRANSPORTER INHIBITOR |
| Indications | Indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate |
| Caution | Lactic acidosis is a metabolic complication that can occur due to metformin accumulation during treatment and is fatal in ~50% of cases. Necrotizing fasciitis of the perineum (Fournier gangrene) repor More ... |
| Dose Range |
Take twice daily with meals (ie, divide total daily dose into 2 doses/day) For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin. |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |